Drug updated on 7/25/2024
Dosage Form | Injection (intramuscular; 300 units, 500 units) |
Drug Class | Multiple |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of cervical dystonia in adults.
- Indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults < 65 years of age.
- Indicated for the treatment of spasticity in patients 2 years of age and older.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Abobotulinumtoxin A (Dysport) is indicated for the treatment of cervical dystonia in adults, temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults under 65 years of age, and treatment of spasticity in patients 2 years of age and older.
- The information was derived from a total of 8 systematic reviews/meta-analyses documents.
- For neurogenic detrusor overactivity (NDO), trends favored higher doses of abobotulinumtoxin A compared to onabotulinumtoxinA but required confirmatory studies due to limited evidence.
- In cosmetic applications for facial aesthetics, high patient satisfaction was observed across various subgroups, including different ages and sexes within adult populations under 65 years old.
- Consistent efficacy and safety profiles were noted for hyperhidrosis treatments across multiple types, such as axillary, palmar, and forehead hyperhidrosis among adult populations without serious adverse events reported.
- Pediatric lower limb spasticity showed significant efficacy advantages over other botulinum toxins like onabotulinumtoxinA with comparable rates of adverse events.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Dysport (abobotulinumtoxin A) Prescribing Information. | 2020 | Ipsen Biopharmaceuticals, Inc., Cambridge, Fort Worth, TX |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Oscar clinical guideline: botulinum toxin. | 2017 | OSCAR |